Maria Backström1, Pirjo Tynjälä2, Heikki Ylijoki3, Kristiina Aalto4, Johanna Kärki5, Heini Pohjankoski6, Paula Keskitalo7, Sirja Sard7, Maiju Hietanen6, Helena Lehto8, Tommi Kauko9, Paula Vähäsalo7. 1. Department of Pediatrics, Vaasa Central Hospital, Vaasa, maria.backstrom@vshp.fi. 2. Poison Information Center, Helsinki University Central Hospital, Helsinki, Department of Pediatrics, South-Karelian Central Hospital, Lappeenranta. 3. Department of Pediatrics, Satakunta Central Hospital, Pori. 4. Children's Hospital, Helsinki University Central Hospital and University of Helsinki, Helsinki. 5. Department of Pediatrics, Kanta-Häme Central Hospital, Hämeenlinna. 6. Department of Pediatrics, Päijät-Häme Central Hospital, Lahti. 7. Medical Research Center Oulu, Department of Children and Adolescents, Oulu University Hospital and PEDEGO Research Center, University of Oulu and. 8. Department of Pediatrics, South-Karelian Central Hospital, Lappeenranta. 9. Department of Biostatistics, University of Turku, Turku, Finland.
Abstract
OBJECTIVES: To establish the cut-off values for inactive disease, as well as low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in non-systemic JIA based on the Juvenile Arthritis Disease Activity Score (JADAS) and assessed with the 10-joint JADAS (JADAS10) and clinical JADAS10 (cJADAS10). METHODS: In a multicentre cross-sectional study consisting of ∼20% of all patients with JIA in Finland (n = 509), we obtained data on their most recent registered visits between January 2013 and January 2014. We calculated the JADAS10 and cJADAS10 and established the cut-off values of both of these scores using two different receiver operating characteristics-based statistical methods. RESULTS: Of the 509 patients studied, 65.8% were females and 53.8% had polyarticular disease. The most suitable method for determining cut-off values was the Youden index. In oligoarticular patients, a JADAS10 score of 0-0.5 represented inactive disease, 0.6-2.7 LDA and ≥2.8 MDA. In polyarticular disease, a JADAS10 score of 0-0.7 represented inactive disease, 0.8-3.9 LDA and ≥4.0 MDA. The cut-off values for HDA were not possible to establish because only two visits fulfilled HDA criteria. CONCLUSION: We established cut-off values for LDA and MDA. A reliable definition for HDA will require more patients. In the clinical setting, both the cJADAS10 and JADAS10 serve equally well both for research and quality control purposes. In the future, uniform clinical disease activity levels should be established. We also suggest revising and validating the criteria for HDA. Valid and robust cut-off values for disease activity levels can guide both clinicians and researchers and equip them for quality control.
OBJECTIVES: To establish the cut-off values for inactive disease, as well as low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in non-systemic JIA based on the Juvenile Arthritis Disease Activity Score (JADAS) and assessed with the 10-joint JADAS (JADAS10) and clinical JADAS10 (cJADAS10). METHODS: In a multicentre cross-sectional study consisting of ∼20% of all patients with JIA in Finland (n = 509), we obtained data on their most recent registered visits between January 2013 and January 2014. We calculated the JADAS10 and cJADAS10 and established the cut-off values of both of these scores using two different receiver operating characteristics-based statistical methods. RESULTS: Of the 509 patients studied, 65.8% were females and 53.8% had polyarticular disease. The most suitable method for determining cut-off values was the Youden index. In oligoarticular patients, a JADAS10 score of 0-0.5 represented inactive disease, 0.6-2.7 LDA and ≥2.8 MDA. In polyarticular disease, a JADAS10 score of 0-0.7 represented inactive disease, 0.8-3.9 LDA and ≥4.0 MDA. The cut-off values for HDA were not possible to establish because only two visits fulfilled HDA criteria. CONCLUSION: We established cut-off values for LDA and MDA. A reliable definition for HDA will require more patients. In the clinical setting, both the cJADAS10 and JADAS10 serve equally well both for research and quality control purposes. In the future, uniform clinical disease activity levels should be established. We also suggest revising and validating the criteria for HDA. Valid and robust cut-off values for disease activity levels can guide both clinicians and researchers and equip them for quality control.
Authors: Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston Journal: Arthritis Care Res (Hoboken) Date: 2019-04-25 Impact factor: 4.794
Authors: Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston Journal: Arthritis Rheumatol Date: 2019-04-25 Impact factor: 10.995
Authors: Maria Backström; Pirjo Tynjälä; Kristiina Aalto; Minna-Maija Grönlund; Heikki Ylijoki; Anne Putto-Laurila; Johanna Kärki; Paula Keskitalo; Sirja Sard; Heini Pohjankoski; Maiju Hietanen; Silke Witter; Helena Lehto; Eliisa Löyttyniemi; Paula Vähäsalo Journal: RMD Open Date: 2019-04-24
Authors: Maria Backström; Pirjo Tynjälä; Kristiina Aalto; Heikki Ylijoki; Anne Putto-Laurila; Minna-Maija Grönlund; Johanna Kärki; Paula Keskitalo; Sirja Sard; Heini Pohjankoski; Maiju Hietanen; Silke Witter; Helena Lehto; Eliisa Löyttyniemi; Paula Vähäsalo Journal: Rheumatol Adv Pract Date: 2018-10-24
Authors: Patricia Vega-Fernandez; Tracy V Ting; Edward J Oberle; Courtney McCracken; Janet Figueroa; Mekibib Altaye; Amy Cassedy; Gurjit S Kaeley; Johannes Roth Journal: Arthritis Care Res (Hoboken) Date: 2021-07-30 Impact factor: 5.178